Cellectis SA (CLLS) AI Stock Analysis

• Market Cap: $276.29M
• Dividend Yield: N/A
• Average Volume (3M): 185.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.94
• Revenue Growth: 334.02%
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 72,093,636
• 10 Day Avg. Volume: 212,821
• 30 Day Avg. Volume: 185,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 1.22
• Enterprise Value/Gross Profit: 1.77
• Enterprise Value/Ebitda: -1.93
• 1Y Price Target: $6.00
• Price Target Upside: 65.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 61 Neutral
• Price Target: $3.50 ▼(-3.58% Downside)

Cellectis SA's overall stock score is driven by its strong technical momentum and positive developments from the earnings call, including strategic partnerships and clinical trial progress. However, financial performance challenges and valuation concerns due to ongoing losses and lack of dividend yield weigh down the score.

Positive Factors

Strategic Partnerships

The partnership with AstraZeneca enhances Cellectis' R&D capabilities and market reach, potentially accelerating the development and commercialization of new therapies.

Clinical Trial Progress

Advancing to Phase II trials signifies progress in clinical validation, increasing the potential for regulatory approval and market entry, crucial for long-term growth.

Cash Position

A strong cash position provides financial stability, enabling continued investment in R&D and operational activities without immediate need for external financing.

Negative Factors

Profitability Challenges

Persistent negative profit margins highlight operational inefficiencies, which could hinder long-term financial sustainability and investor confidence.

Revenue Consistency

Inconsistent revenue growth can affect financial planning and stability, potentially impacting the company's ability to fund future projects and expansions.

Servier Arbitration Uncertainty

Legal disputes can create financial and operational uncertainties, potentially diverting resources and focus from core business activities and strategic goals.

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

How the Company Makes Money

Cellectis generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. The company primarily earns money by entering into strategic alliances that provide funding for research and development in exchange for rights to commercialize its gene-editing technologies and products. Additionally, Cellectis may receive milestone payments and royalties based on the commercial success of therapies developed using its technologies. Significant partnerships with major players in the pharmaceutical industry contribute to its revenue streams, as well as potential advancements in clinical trials that lead to further business opportunities.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA shows mixed financial health with stable liquidity and cash management but ongoing challenges in profitability and revenue consistency. The balance sheet indicates a stable but declining equity position, while cash flow improvements provide a positive outlook amid persistent net losses.

Income Statement

The company shows a fluctuating revenue trend, with a significant decline from 2021 to 2023, followed by a recovery in 2024 and TTM. Gross profit margin is relatively stable but net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. The equity ratio has been declining, which might indicate increasing liabilities relative to assets. Despite this, the company maintains a solid cash position, which can be advantageous for liquidity.

Cash Flow

Positive developments in cash flow are noted, with operating cash flow turning positive in recent periods. The free cash flow growth is encouraging, although the company has historically faced negative free cash flows. The ratio of operating cash flow to net income is favorable, highlighting efficient cash management despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.51M	41.51M	755.00K	19.17M	73.95M	73.95M
Gross Profit	38.86M	21.63M	18.00K	17.40M	37.67M	37.67M
EBITDA	-35.61M	-15.84M	-92.64M	-76.38M	-86.46M	-34.68M
Net Income	-59.30M	-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet
Total Assets	353.97M	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	198.15M	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	113.83M	91.46M	92.85M	82.85M	102.24M	111.30M
Total Liabilities	256.86M	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	97.11M	131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow
Free Cash Flow	-25.98M	19.15M	-25.82M	-89.89M	-124.31M	-126.52M
Operating Cash Flow	-23.04M	22.99M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	9.89M	-102.81M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	-5.38M	89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 3.63 is below the 20-day moving average (MA) of 3.85, above the 50-day MA of 3.31, and above the 200-day MA of 2.06, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 50.10 is Neutral, neither overbought nor oversold. The STOCH value of 14.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.

Cellectis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	―	$276.29M	-6.37	-48.36%	―	334.02%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZURA	―	$239.92M	-4.86	-46.33%	―	―	-50.20%
FHTX	―	$230.08M	-3.28	―	―	-31.30%	36.26%
RNAC	―	$216.34M	-0.16	―	―	―	―
TNYA	―	$270.54M	-1.73	-85.21%	―	―	38.94%
VOR	―	$184.20M	―	―	―	―	-686.12%

Cellectis SA Corporate Events

Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL

On October 16, 2025, Cellectis S.A. hosted an Investors R&D Day, unveiling promising data from the Phase 1 BALLI-01 study of lasme-cel (UCART22) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed lasme-cel was generally well-tolerated and demonstrated significant efficacy, with a 68% overall response rate and 83% achieving minimal residual disease-negative status in the target Phase 2 population. The company announced the initiation of the pivotal Phase 2 trial and outlined a registration path for lasme-cel as a bridge to transplant in r/r ALL, with a Biologics License Application submission anticipated in 2028. This development positions lasme-cel as a potential game-changer in the industry, offering a new treatment option for heavily pretreated patients and potentially capturing a significant share of the market.

Cellectis Showcases Pipeline Progress at R&D Day

On October 16, 2025, Cellectis hosted an R&D Day in New York City, where the company presented the full Phase 1 dataset and outlined the pivotal Phase 2 trial design for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This event highlighted the commercial opportunities and strategic advancements in their pipeline, reinforcing Cellectis’ position in the biotechnology industry as a leader in gene-editing therapies. The presentation of the Phase 1 data and the strategy for Phase 2 trials are significant for stakeholders, as they indicate potential market opportunities and the company’s progress in developing effective treatments for cancer.

Cellectis Unveils Promising Gene Therapy Advances at ESGCT Congress

Cellectis announced the presentation of new research findings at the ESGCT Annual Congress in Sevilla, Spain, from October 7-10, 2025. The company highlighted the potential of circular single-stranded DNA (CssDNA) as a non-viral template for gene therapy, demonstrating high gene insertion frequency and better engraftment in HSPCs compared to viral methods. Additionally, Cellectis presented a study on TALE base editors, showing no significant off-target effects, supporting their safe use in therapeutic applications. These advancements could enhance Cellectis’ position in the gene therapy industry and offer new opportunities for stakeholders.

Cellectis S.A. Reports Interim Financial Results for First Half of 2025

Cellectis S.A. released its interim financial report for the six-month period ending June 30, 2025, showcasing its financial position and performance. The report highlights a significant increase in non-current financial assets and other non-current assets, reflecting the company’s strategic investments and growth. This financial update provides stakeholders with insights into Cellectis’s operational progress and its positioning within the biotechnology industry.

Cellectis Reports Q2 2025 Financials and Key Clinical Milestones

Cellectis S.A. announced its second-quarter 2025 financial results and business updates, highlighting key developments in its clinical programs and strategic partnerships. The company completed end-of-Phase 1 meetings with the FDA and EMA for its UCART22 therapy in relapsed or refractory B-cell acute lymphoblastic leukemia, paving the way for a pivotal Phase 2 trial in the second half of 2025. Additionally, Cellectis is advancing its collaboration with AstraZeneca and expects significant milestones in its ongoing clinical trials, including a Phase 1 readout for UCART20x22 in late 2025. Financially, Cellectis reported $230 million in cash and equivalents as of June 30, 2025, providing a runway into the second half of 2027.

Cellectis to Announce Q2 2025 Financial Results on August 4

On July 28, 2025, Cellectis announced it will release its second-quarter financial results for 2025 on August 4, 2025, after the US market closes. The announcement will be followed by an investor conference call and webcast on August 5, 2025, which will cover the company’s financial performance and business updates. This event is significant for stakeholders as it provides insights into Cellectis’ operational progress and strategic direction in the biotechnology sector.